In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

Researchers sought to determine the most appropriate P2Y12 inhibitor therapy in patients with acute coronary syndrome.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

Dr Ray O’Connor contines his look at recent clinical articles on therapeutics, particlularly in the fields of cardiology, and ...

Supplements such as vitamin E, ginkgo, garlic, ginger, and omega-3s are among those that can interact with blood-thinning medications.

Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly ...

Glorious Dexa Mandaya Philippines, the Philippine subsidiary of Indonesia’s Dexa Group, is experiencing rapid uptake of its ...

A landmark trial by an Indian doctor, involving the largest head-to-head comparison of two major anti-platelet drugs in ...

People readily consume it in any form, be it juice, pickle, powder, or supplement. But one thing most people do not know is that eating Amla is not beneficial for everyone. Yes, while it is healthy, ...

Major medical study reveals clopidogrel prevents heart attacks 14% better than aspirin with no extra bleeding risk.

Missing data in clinical trials remains an ongoing concern. With the expansion of data privacy efforts and the consequent inability to contact trial participants for follow-up, the magnitude and ...